Firethorn Wealth Partners LLC increased its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 6.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,213 shares of the exchange traded fund’s stock after acquiring an additional 615 shares during the period. Firethorn Wealth Partners LLC’s holdings in SPDR S&P Biotech ETF were worth $847,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the stock. Provident Wealth Management LLC raised its holdings in SPDR S&P Biotech ETF by 3,000.0% in the first quarter. Provident Wealth Management LLC now owns 310 shares of the exchange traded fund’s stock valued at $25,000 after buying an additional 300 shares during the period. DHJJ Financial Advisors Ltd. purchased a new position in SPDR S&P Biotech ETF in the second quarter valued at approximately $25,000. Garrison Bradford & Associates Inc. purchased a new position in SPDR S&P Biotech ETF in the first quarter valued at approximately $39,000. Compass Wealth Management LLC raised its holdings in SPDR S&P Biotech ETF by 46.0% in the first quarter. Compass Wealth Management LLC now owns 635 shares of the exchange traded fund’s stock valued at $51,000 after buying an additional 200 shares during the period. Finally, Golden State Wealth Management LLC raised its holdings in SPDR S&P Biotech ETF by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 638 shares of the exchange traded fund’s stock valued at $52,000 after buying an additional 319 shares during the period.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $103.60 on Friday. SPDR S&P Biotech ETF has a one year low of $66.66 and a one year high of $105.47. The company’s 50 day moving average price is $92.10 and its 200 day moving average price is $85.15. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of 11.47 and a beta of 0.97.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why the Precious Metal Nobody Talks About Could Be Your Best Bet
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
- Large Cap Stock Definition and How to Invest
- 3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.